scispace - formally typeset
K

Keita Hirai

Researcher at University of Shizuoka

Publications -  121
Citations -  839

Keita Hirai is an academic researcher from University of Shizuoka. The author has contributed to research in topics: Asthma & Internal medicine. The author has an hindex of 12, co-authored 107 publications receiving 601 citations. Previous affiliations of Keita Hirai include Boston Children's Hospital & Chiba University.

Papers
More filters
Journal ArticleDOI

Antinociceptive effects of St. John's wort, Harpagophytum procumbens extract and Grape seed proanthocyanidins extract in mice.

TL;DR: It is shown that SJW, HPE and GSPE exert significant antinociceptive effects in the formalin test of mice, and opioidergic system seems to be involved in the antinOCiceptive effect of HPE but not SJW and G SPE.
Journal ArticleDOI

Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.

TL;DR: Augmented renal clearance was strongly associated with VCM pharmacokinetics, and two-thirds of the ARC patients had subtherapeutic VCM concentrations, and the patients with ARC exhibited higher VCM clearance values than the non-ARC patients.
Journal ArticleDOI

Combined Assessment of Serum Periostin and YKL-40 May Identify Asthma-COPD Overlap.

TL;DR: Results revealed that older age, lower body mass index, higher eosinophil counts, higher total IgE, and the absence of the diagnosis of COPD were significantly associated with higher periostin levels.
Journal ArticleDOI

Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance.

TL;DR: It is concluded that febrile neutropenia, a significant risk factor for ARC, indirectly influenced VCM clearance towing to an elevated eGFR.
Journal ArticleDOI

Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.

TL;DR: This method is suitable for assessing the risk/benefit of combination therapy in the pediatric population and useful for therapeutic drug monitoring for PAH treatment and applied to a clinical pharmacokinetic study in pediatric patients with pulmonary arterial hypertension (PAH).